Search
Search Results
-
New β-Lactam-β-Lactamase Inhibitor Combinations
To meet the challenge of treating increasing prevalence of multiresistant and carbapenem-resistant gram-negative bacteria, pharmaceutical companies...
-
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations
The use of β-lactam (BL) and β-lactamase inhibitor (BLI) combinations, such as piperacillin-tazobactam (PIP-TAZ) is an effective strategy to combat...
-
Identification of α-mangostin as a potent inhibitor of β-lactamase OXA-48
The production of carbapenemases is a significant mechanism contributing to carbapenem resistance in Enterobacteriaceae . Among these carbapenemases,...
-
Extended-Spectrum β-Lactamase and AmpC β -Lactamase-Producing Bacteria in Livestock Animals
In the past decades, we faced a rapid increase in human infections caused by third-generation cephalosporin-resistant bacteria, e.g., Escherichia...
-
Extended-Spectrum β-Lactamase and AmpC β-Lactamase-Producing Bacteria in Livestock Animals
In the past decades, we faced a rapid increase in human infections caused by third-generation cephalosporin-resistant bacteria, e.g., Escherichia...
-
β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria
Antibiotic resistance induced by β-lactamase is posing a significant problem to the pharmaceutical industry. For the last 30 years, only a few...
-
Carbapenem or new β-lactam-β-lactamase inhibitors? An Italian survey supported by SITA, SIMIT and SIAARTI to identify the factors affecting empiric antimicrobial therapy choice in real-life clinical practice
While a tailored antibiotic treatment plan is often straightforward, what we often observe in daily clinical practice is a highly variable approach...
-
In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept
PurposeNacubactam (NAC) is a novel diazabicyclooctane β-lactamase inhibitor used in combination with cefepime (CFPM). In this study, we aimed to...
-
Genomic diversity of β-lactamase producing Pseudomonas aeruginosa in Iran; the impact of global high-risk clones
BackgroundHospital-acquired infections caused by multidrug-resistant Pseudomonas aeruginosa incline hospital stay and costs of treatment that...
-
In vitro and in vivo evaluation of two combined β-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii
The objective of this study was to evaluate the in vitro and in vivo efficacy of clavulanic acid (C/A) in combination with tazobactam against...
-
Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya
BackgroundBacterial infections in COVID-19 patients, especially those caused by multidrug-resistant gram-negative strains, are associated with...
-
Characterization of class 1 integrons in metallo-β-lactamase-producing Acinetobacter baumannii isolates from hospital environment
Background and ObjectiveThe emergence and widespread dissemination of antibiotic resistance in A. baumannii , has become a globally challenge. The...
-
Empirical treatment and mortality in bacteremia due to extended spectrum β-lactamase producing Enterobacterales (ESβL-E), a retrospective cross-sectional study in a tertiary referral hospital from Colombia
BackgroundInfections caused by extended spectrum β-lactamase (ESβL) producing bacteria are common and problematic. When they cause bloodstream...
-
Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales
The combination of ceftazidime-avibactam (CAZ-AVI) and aztreonam (ATM) is used to treat MBL-producing Enterobacterales-related infections. The new...
-
Dissemination of mcr-1 and β-lactamase genes among Pseudomonas aeruginosa: molecular characterization of MDR strains in broiler chicks and dead-in-shell chicks infections
ObjectivesPseudomonas aeruginosa ( P. aeruginosa) is one of the most serious pathogens implicated in antimicrobial resistance, and it has been...
-
Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region
BackgroundAntibiotic resistance is one of the most serious global health problems and threatens the effective treatment of bacterial infections. Of...
-
Clinical and cost-effectiveness analysis of carbapenems versus ciprofloxacin in the treatment of urinary tract infections due to extended spectrum β-lactamase-producing Enterobacterales
BackgroundUrinary tract infections (UTIs) are the most common infectious diseases in both hospital and community settings. The management of UTIs...
-
Epidemiology of extended-spectrum β-lactamase–producing Enterobacterales infection in kidney transplant recipients
BackgroundExtended-spectrum b-lactamase (ESBL)-producing gram-negative bacilli (ESBL-GNB) are the most important pathogenic bacteria infecting kidney...
-
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020
Pseudomonas aeruginosa isolates were consecutively collected from patients with pneumonia in 29 medical centers in 2020 and susceptibility tested by...
-
High carriage rate of extended‐spectrum β‐lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation
The safety of fecal microbiota transplantation (FMT) has been highlighted by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli ...
